Form 4: Centessa Pharmaceuticals CFO Granted Stock Options

John J. Crowley, Chief Financial Officer of Centessa Pharmaceuticals, was granted stock options for 600,000 ordinary shares on July 1, 2024.

Summary

• John J. Crowley, the Chief Financial Officer of Centessa Pharmaceuticals plc, was granted a share option on July 1, 2024.
• The option allows him to purchase 600,000 ordinary shares at an exercise price of $8.80.
• 25% of the shares will vest on July 1, 2025, and the remaining 75% will vest in 36 monthly installments thereafter.
• The share option expires on July 1, 2034.
• A Power of Attorney was also filed, authorizing Iqbal Hussain, Gregory Weinhoff, and Richard Menziuso to act on Crowley's behalf for SEC filings.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize and retain key executives. This grant aligns with standard compensation practices in the sector.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are generally in line with industry norms for similar-sized companies.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CFO to improve company performance.
• Employees may see this as a sign of confidence in the company's future.

Key Dates